This from USTR’s 2010 Trade Policy Agenda and 2009 Annual Report:
The United States has also continued to engage Taiwan on concerns raised by the pharmaceutical and medical device industries that Taiwan’s procedures for medical product pricing and reimbursement fail to adequately recognize the value of innovative medical products for patients in Taiwan. The United States encourages Taiwan to continue to engage in collaborative consultations with relevant stakeholders to consider improving such policies in order to better facilitate the development of innovative products and improve patients’ access to such products.
